TABLE 1. Summary of 149 immunodeficiency-associated vaccine-derived poliovirus (iVDPV) cases reported in the World Health Organization (WHO) iVDPV registry — worldwide, January 1, 1961–December 31, 2019*.
| Characteristic | No. (%) |
|---|---|
| iVDPV cases reported to WHO (1961–2019) |
149 (100) |
|
Period detected
| |
| 1961–2000 |
19 (12.8) |
| 2001–2010 |
31 (20.8) |
| 2011–2020 |
99 (66.4) |
|
WHO region
| |
| African |
10 (6.7) |
| Eastern Mediterranean |
74 (49.7) |
| European |
16 (10.7) |
| Americas |
18 (12.1) |
| South-East Asian |
15 (10.1) |
| Western Pacific |
16 (10.7) |
|
Sex
| |
| Female |
64 (40.6) |
| Male |
85 (59.4) |
|
Acute flaccid paralysis
| |
| Yes |
95 (63.8) |
| No |
51 (34.2) |
| Unknown |
3 (2.0) |
|
Age group at onset (yrs)
| |
| <1 |
86 (59.3) |
| 1–5 |
40 (27.6) |
| >5 |
19 (13.1) |
|
Immunodeficiency category
| |
| Antibody disorders (HGG, AGG, XLA) |
39 (28.1) |
| Common variable immunodeficiency |
22 (15.8) |
| SCID and other combined humoral/T-cell deficiencies |
46 (33.1) |
| Other (MHC class II deficiency, centromere instability, ICF syndrome) |
20 (14.4) |
| Unknown |
12 (8.6) |
|
Serotype
| |
| 1 |
27 (18.1) |
| 2 |
83 (55.7) |
| 3 |
33 (22.1) |
| 1 and 2 |
3 (2.0) |
| 2 and 3 |
3 (2.0) |
|
Outcome
| |
| Alive |
16 (10.7) |
| Alive and stopped excreting |
52 (34.9) |
| Dead |
65 (43.6) |
| Unknown/Lost to follow-up | 16 (10.7) |
Abbreviations: AGG = agammaglobulinemia; HGG = hypogammaglobulinemia; ICF = centromeric region instability, facial anomalies syndrome; MHC = major histocompatibility complex; SCID = severe combined immunodeficiency; XLA = X-linked agammaglobulinemia.
*Data as of May 17, 2020.